SNPX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	6 874.00
Vidutinė apimtis	49 649.00
Rinkos kapitalizacija	4.92M
EPS	$0 ( 2024-04-02 )
Kita pelno data	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.150
ATR14	$0.0750 (1.66%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Singer William S.	Buy	800	Stock Option (Right to Buy)
2024-04-08	Silverman Joshua	Buy	800	Stock Option (Right to Buy)
2024-04-08	Schechter Jonathan	Buy	800	Stock Option (Right to Buy)
2024-04-08	Bernstein Bruce	Buy	800	Stock Option (Right to Buy)
2023-03-29	Schechter Jonathan	Buy	20 000	Stock Option (Right to Buy)

INSIDER POWER
74.96
Last 71 transactions
Buy: 1 845 200 \| Sell: 283 116

Synaptogenix, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GOSS	0.958
VORB	0.946
BCAB	0.946
THTX	0.944
XFOR	0.943
FATE	0.942
NVTSW	0.941
RIVN	0.939
NCBS	0.938
ISPO	0.938

10 Labiausiai neigiamai susiję koreliacijos
NWLI	-0.967
AMYT	-0.967
EZGO	-0.959
RXDX	-0.956
TACO	-0.956
MLCO	-0.955
LUNA	-0.954
HZNP	-0.953
EXAS	-0.953
MLVF	-0.953

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Synaptogenix, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-6 347.00 (0.00 %)
EPS:	$-12.96

FY	2023
Pajamos:	$0
Bruto pelnas:	$-6 347.00 (0.00 %)
EPS:	$-12.96

FY	2022
Pajamos:	$0
Bruto pelnas:	$-5 714.00 (0.00 %)
EPS:	$-0.780

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.51

Financial Reports:

No articles found.

Synaptogenix, Inc.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.